Alnylam Pharmaceuticals, Inc.
ALNY
#797
Rank
$31.980 B
Marketcap
United States
Country
$239.00
Share price
8.05%
Change (1 day)
-46.07%
Change (1 year)
Categories
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria;…
Key Metrics
Trailing P/E
43.32
Forward P/E
19.94
EPS (TTM)
$5.74
Forward EPS
$12.47
Price / Book
24.56
EV / EBITDA
31.3x
Beta
0.30
Dividend Yield
—
Return on Equity
96.56%
Return on Assets
12.34%
Debt / Equity
220.62
Current Ratio
3.06
Gross Margin
79.65%
Operating Margin
17.93%
Net Profit Margin
16.13%
Free Cash Flow
$271.544M
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 17 – Sep 11
+10.72%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$3.714B
Latest Net Income$313.747M
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Alnylam Pharmaceuticals, Inc. with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
ALNY
No recent news available. Set FINNHUB_API_KEY to enable news.
